A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

Trial Details

NCT ID
NCT06692738
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Rilvegostomig
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
  • Nab-paclitaxel
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Anaheim, California, United States|33.83529,-117.9145
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Loma Linda, California, United States|34.04835,-117.26115

Key Eligibility Criteria

  • Histologically or cytologically documented squamous NSCLC.
  • Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
  • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any actionable driver oncogenes for…
  • Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →